<div id="readability-page-1"><div>         <div>                        <p>,  /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China.</p>             <p><span>                 Continue Reading                   <br/>                   <i></i>                                </span>             </p>             <div>               <div>                 <div>                                       <div>                                                               <figure>                        <p><img id="imageid_2" src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/>                    </p>                       <figcaption>         Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, stands on the patient’s right. The patient’s daughter, nursing team, medical team, and caregivers are gathered together at Jiahui International Hospital.       </figcaption>     </figure>                                                                                  </div>                 </div>               </div>             </div>             <p>The 70‑something patient had exhausted all standard lines of treatment at MD Anderson Cancer Center in the United States. His doctors recommended ivonescimab, the first approved PD‑1/VEGF bispecific antibody for solid tumors. After a video consultation in late November scheduled within a week of their initial inquiry, the family chose Jiahui International Cancer Center in Shanghai for its multidisciplinary expertise and U.S.‑trained Medical Oncology Chief Dr. XUAN Linli.</p>                            <p>During treatment, the patient developed immune‑related complications requiring ICU care. The cancer center rapidly coordinated oncology, neurology, critical care, and expert input from ivonescimab principal investigator Dr. Zhou Caicun. His condition has since stabilized, with ongoing care focused on disease control.</p>               <p>As a tertiary international hospital partnered with Massachusetts General Hospital Cancer Center, Jiahui provides seamless international patient pathways, from remote consultations to travel coordination and continuous family updates.</p><p>The patient's daughter said, &#34;We are deeply grateful for the dedication, compassion, and tireless efforts of the entire Jiahui team: the doctors, nurses, kitchen and cleaning staff, the international team and front desk, and the <span id="spanHghlteeab">care aides</span>. My father would especially like to express his heartfelt thanks to <span id="spanHghlta5b2">Ms. Cui, who </span>has cared for him every day since his admission. Beyond her attentive bedside care, she has offered him encouragement, comfort, and hope.&#34;</p><p>China's breakthrough oncology innovations are creating new options for patients worldwide. JICC continues to draw growing inquiries and referrals from North America, Europe, Asia and the Middle East, establishing Shanghai as a global hub for advanced cancer care.</p><p><span id="spanHghlt7f82">The fu</span>ll story: https://jiahui.com/en/news/181</p><p><b>Contact:</b></p><p><b>International Patient Services</b></p><p><span id="spanHghlt793c">inter</span><span>[email protected]</span></p><p>WhatsApp: +852 4619 1904</p><p>SOURCE Jiahui International Hospital</p><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzA2Jk5ld3NJdGVtSWQ9Q04wMzI0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDYyMzE5UFJfTkVXU19VU1BSX19fX19DTjAzMjQ0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzA2Jk5ld3NJdGVtSWQ9Q04wMzI0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDYyMzE5UFJfTkVXU19VU1BSX19fX19DTjAzMjQ0"/></p></div>       </div></div>

09926

560600

520690

<p>Jiahui International Cancer Center (JICC) in China has successfully stabilized a U.S. patient with advanced non-small cell lung cancer (NSCLC) using ivonescimab, a novel immunotherapy. The patient, who had previously exhausted all standard treatments, received care from a multidisciplinary team, including U.S.-trained oncologists. Despite developing complications requiring ICU care, the patient's condition has stabilized. JICC is gaining recognition as a global hub for advanced cancer care, attracting patients from around the world.</p>

prnewswire

AKESO

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

23:20 ETU.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China